Pinpointing Phase III Trials in Emerging Countries
Most clinical trial activity for Phase III trials takes place in the traditional North American and European markets.
Phase III patient enrollment represents one of the most critical business issues facing the pharmaceutical industry. In recent years there has been extensive discussion about the growing use of newer geographies for Phase III clinical study sites. Many of these newer geographies in areas such as Asia, South Asia, Latin America and Africa may represent increasingly attractive commercial markets for pharmaceutical companies. But more critically for drug development professionals, these areas present the prospect of large pools of medially naïve patients who can be enrolled at quicker rates and at lower costs. At many conferences speakers, particularly from larger pharmaceutical companies and CROs discuss the opportunities and challenges for clinical trial completion represented by these new geographies.
Clinical site selection is primarily driven by that site’s ability to enroll and tread patients in accord with the study protocol. Certainly though a market’s commercial attractiveness may also be a consideration. Larger pharmaceutical companies are probably better equipped to launch drugs in the newer geographies. The data from the federally mandated fields in ClinicalTrials.gov do show that the very largest pharmaceutical companies are more likely to conduct clinical trials outside the traditional geographies of North America. But like the rest of the industry, most of the clinical trial activity remains within North America and Europe. Moreover, there has been no appreciable increase in the use of newer geographies by either larger or smaller companies.
Harold E. Glass, PhD, Dean's Professor, University of the Sciences in Philadelphia
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
